Artificial intelligence and single-use technologies (SUTs) are converging across biopharmaceutical manufacturing as global corporate AI investment reached $252.3 billion in 2024. BCC Research says private AI investment rose 44.5% and mergers and acquisitions activity increased 12.1%, with the U.S. accounting for $109.1 billion in private investment versus China’s $9.3 billion. Total AI investment has increased more than 13-fold since 2014. More than 60% of biopharmaceutical manufacturers are using AI- and Internet of Things-enabled solutions for process monitoring and control, cutting costs and development timelines by up to 30% to 50%. Digital twins, AI-powered single-use bioreactors, Process Analytical Technology integrated with machine learning, and autonomous manufacturing are advancing continuous quality control and predictive optimization. Asia-Pacific adoption is being supported by initiatives including Singapore’s National Precision Medicine Strategy and Thailand 4.0, while contract development and manufacturing organizations and Global Capability Centers are prominent adopters. Major companies and specialist innovators are investing across the sector, including Novartis’ $3 billion commitment with Isomorphic Labs, Sanofi’s $1.2 billion commitment with Insilico Medicine, Eli Lilly’s $1 billion co-investment with NVIDIA, Lila Sciences’ $350 million Series A, Basetwo’s $11.5 million fundraising and Lemnisca’s pre-seed financing. Risks include single-use infrastructure and standardization constraints, European regulatory headwinds, data silos and fragmented pharmaceutical platforms.